SCHEMBL6929931

SCHEMBL6929931

O=C(Nc1ccccn1)c1ccc(OCc2cccnc2)nc1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 3/20 0.61
RAB9A P51151 4/20 0.53
NPC1 O15118 3/20 0.53
SGMS2 Q8NHU3 1/20 0.50
F2 P00734 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
CXCR1 P25024 1/20 0.47
GCK P35557 1/20 0.47
CHRNB2 P17787 1/20 0.46
CHRNB4 P30926 1/20 0.46
CHRNA3 P32297 1/20 0.46
CHRNA4 P43681 1/20 0.46
TSHR P16473 1/20 0.46
GPR132 Q9UNW8 1/20 0.46
NAMPT P43490 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6927775 0.91 CXCR2 (0.73) CXCR2RAB9ANPC1SGMS2F2
SCHEMBL6930026 0.88 CXCR2 (0.64) CXCR2RAB9ANPC1SGMS2F2
SCHEMBL6930364 0.84 CXCR2 (0.74) CXCR2RAB9ANPC1SGMS2F2
SCHEMBL6930256 0.84 CXCR2 (0.58) CXCR2RAB9ANPC1SGMS2F2
SCHEMBL6931210 0.81 CXCR2 (0.69) CXCR2RAB9ASGMS2MEN1KMT2A
SCHEMBL6927759 0.80 CXCR2 (0.60) CXCR2RAB9ANPC1F2MEN1
SCHEMBL840850 0.79 MAPT (0.59) CXCR2KMT2AGPR132
SCHEMBL6646471 0.79 RAB9A (0.70) RAB9ANPC1F2MEN1KMT2A
SCHEMBL31414959 0.79 RAB9A (0.70) RAB9ANPC1F2MEN1KMT2A
SCHEMBL12633969 0.78 HDAC1 (0.71) NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-07-28 US disclosed
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-07-28 US disclosed
WO-2011035324-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS VANDERBILT UNIVERSITY (US) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS GRM5, GRIK5, GRM1 CXCR2 2454/4885RAB9A 1383/4885NPC1 1371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.